Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Oncolytics Biotech (ONCY) Reports Q3 Loss of $0.16
November 11, 2020 4:52 PM ESTOncolytics Biotech (NASDAQ: ONCY) reported Q3 EPS of ($0.16), versus ($0.16) reported last year.
Financial Highlights
As of September 30, 2020, the Company reported $26.7 million in cash and cash equivalents. The Company raised $3.6 million during the third quarter through the issuing of common stock through our ATM facility.Operating expense for the third quarter of 2020 was $2.5 million, compared to $1.8 million in the third quarter of 2019.R&D expense for the third quarter of 2020 was $3.9 million, compared to $1.7 million in the third quarter of 2019.Net cash used in operating activities for the third... More